Extension for Caeneus Mineral’s Mount Roe agreement

Published 28-FEB-2018 12:08 P.M.

|

3 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

Having announced it would be entering into a sale and purchase agreement for the full acquisition of Mt Roe Mining Pty Ltd (being the holder of E47/3846 Roberts Hill Project and E45/5041 Mt Berghaus Project), Caeneus Minerals (ASX:CAD) yesterday reported it had executed a further agreement for an extension of the transaction expiry date.

The new date is 28 May 2018, which concurrently is the newly agreed upon date for CAD’s agreement with RM Corporate Finance Pty Ltd for its corporate advisory mandate.

The company sought both extensions to provide it with more time to hold a general meeting of shareholders following the lifting of its current suspension. This will allow CAD’s shareholders the chance to consider and vote on resolutions relating to the acquisition of Mt Roe Mining.

Overall this is an early stage play and as such any investment decision should be made with caution and professional financial advice should be sought.

In its most recent quarterly report released 31 January, the company provided the following updates on its portfolio of projects.

Columbus Marsh lithium brine project

During the quarter, the company undertook drilling at the Columbus Marsh project, and intersected lithium brines assaying up to 95.9mg/l for the drilled interval of 260 to 280 feet (79.24 – 85.34 meters).

The single drillhole, from 200 feet (70 meters) to end of hole at 830 feet (253 metres), contained anomalous lithium with the lowest assay being 20.6g/ml for the interval 220 to 240 feet (67 to 73 meters). The interval 260 to 340 feet (79 to 103 meters) averaged 80.78g/l lithium, an encouraging result for the budding explorer.

In addition to lithium, the drillhole samples were found to contain very high concentrations of boron and potassium. The interval 79 to 103 meters averaged 3,100 g/l potassium and 851 g/l boron, with the highest recorded values for potassium and boron in the drillhole being 3,800g/l and 1,360g/l respectively.

Rhodes Marsh lithium brine project

Following CAD’s involvement in the Columbus Marsh project, it took steps to acquire mineral rights to the similar Rhodes Marsh area approximately 20 kilometres to the north. The company is now planning a drilling program for the site to coincide with drilling at Columbus Marsh.

Pilbara Gold

In a move to bolster its position in the Pilbara region, CAD acquired three further exploration licence applications in addition to its existing Pardoo project.

The new tenements are considered to have potential both for conglomerate gold and ‘traditional’ gold mineralisation. The first of the acquisitions is a single exploration licence application situated approximately 40 kilometers southwest of Port Hedland — referred to as the Yule River project.

The second is the Roberts Hill tenement application situated approximately 50 kilometres west-southwest of Port Hedland and adjoins ELA 47/5041, Mount Berghaus, to the northeast. The third tenement is situated only three kilometres north of De Grey Mining’s Indee gold deposit of 18.84Mt at 1.7g/t gold and 15 kilometres from the Loudens Patch conglomerate gold discovery.

tags

GOLD


General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X